These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 8405514

  • 21. Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist.
    Donderwinkel PF, Schoot DC, Pache TD, de Jong FH, Hop WC, Fauser BC.
    Hum Reprod; 1993 Dec; 8(12):2027-32. PubMed ID: 8150898
    [Abstract] [Full Text] [Related]

  • 22. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L, Tournaye H, Stoop D, Van Vaerenbergh I, Bourgain C, Polyzos NP, Haentjens P, Blockeel C.
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [Abstract] [Full Text] [Related]

  • 23. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M, Flamigni C, Meriggiola MC, Ferrari P, Michelacci L, Campaniello E, Valdiserri A, Cognigni G.
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [Abstract] [Full Text] [Related]

  • 24. [Effect of basal serum luteinizing hormone and luteinizing hormone/follicle-stimulating hormone ratio on outcomes of in vitro fertilization-embryo transfer in patients with polycystic ovarian syndrome].
    Geng X, Ou X, Liao Y, Tan W, Wang S, Quan S.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):857-60. PubMed ID: 23803197
    [Abstract] [Full Text] [Related]

  • 25. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome.
    Dale PO, Tanbo T, Haug E, Abyholm T.
    Hum Reprod; 1998 Mar; 13(3):567-70. PubMed ID: 9572412
    [Abstract] [Full Text] [Related]

  • 26. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety.
    Ashrafi M, Kiani K, Ghasemi A, Rastegar F, Nabavi M.
    Arch Gynecol Obstet; 2011 Dec; 284(6):1431-8. PubMed ID: 21210134
    [Abstract] [Full Text] [Related]

  • 27. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
    Hosseini MA, Aleyasin A, Saeedi H, Mahdavi A.
    J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
    [Abstract] [Full Text] [Related]

  • 28. Serum FSH bioactivity and response to acute gonadotrophin releasing hormone (GnRH) agonist stimulation in patients with polycystic ovary syndrome (PCOS) as compared to control groups.
    Méchain C, Cédrin I, Pandian C, Lemay A.
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):311-20. PubMed ID: 8458103
    [Abstract] [Full Text] [Related]

  • 29. Polycystic ovary syndrome: low-dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients.
    Dale PO, Tanbo T, Haug E, Abyholm T.
    Hum Reprod; 1992 Sep; 7(8):1085-9. PubMed ID: 1400931
    [Abstract] [Full Text] [Related]

  • 30. [Treatment options of clomiphene-resistant polycystic ovary syndrome related infertility].
    Liang X, Zhuang G, Zhou C.
    Zhonghua Fu Chan Ke Za Zhi; 2000 Oct; 35(10):591-3. PubMed ID: 11372407
    [Abstract] [Full Text] [Related]

  • 31. Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women.
    Cheung AP, Chang RJ.
    Hum Reprod; 1995 May; 10(5):1054-9. PubMed ID: 7657740
    [Abstract] [Full Text] [Related]

  • 32. What is the best treatment for women with polycystic ovarian syndrome and high LH/FSH ratio? A comparison among in vitro fertilization with GnRH agonist, GnRH antagonist and in vitro maturation.
    Ganor-Paz Y, Friedler-Mashiach Y, Ghetler Y, Hershko-Klement A, Berkovitz A, Gonen O, Shulman A, Wiser A.
    J Endocrinol Invest; 2016 Jul; 39(7):799-803. PubMed ID: 26797707
    [Abstract] [Full Text] [Related]

  • 33. Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome.
    Larsen T, Larsen JF, Schiøler V, Bostofte E, Felding C.
    Fertil Steril; 1990 Mar; 53(3):426-31. PubMed ID: 2106449
    [Abstract] [Full Text] [Related]

  • 34. Simultaneous evaluation of basal FSH and oestradiol response to GnRH analogue (F-G-test) allows effective drug regimen selection for IVF.
    Ranieri DM, Phophong P, Khadum I, Meo F, Davis C, Serhal P.
    Hum Reprod; 2001 Apr; 16(4):673-5. PubMed ID: 11278216
    [Abstract] [Full Text] [Related]

  • 35. Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease: hormonal evaluations and clinical perspectives.
    Remorgida V, Venturini PL, Anserini P, Lanera P, De Cecco L.
    Am J Obstet Gynecol; 1989 Jan; 160(1):108-13. PubMed ID: 2492145
    [Abstract] [Full Text] [Related]

  • 36. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle.
    Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL.
    J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683
    [Abstract] [Full Text] [Related]

  • 37. The value of laboratory tests and ultrasonography in evaluating ovarian response to ovulation induction treatment with low-dose recombinant follicle-stimulating hormone.
    Ozkaya O, Kaya H, Sezik M, Akyürek C, Ozbaşar D.
    Int J Fertil Womens Med; 2004 May; 49(2):83-7. PubMed ID: 15188834
    [Abstract] [Full Text] [Related]

  • 38. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M, Liz-Lestón J, Lado-Abeal J.
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [Abstract] [Full Text] [Related]

  • 39. Suppression in the secretion of follicle-stimulating hormone and luteinizing hormone, and ovarian follicle development in heifers continuously infused with a gonadotropin-releasing hormone agonist.
    Gong JG, Campbell BK, Bramley TA, Gutierrez CG, Peters AR, Webb R.
    Biol Reprod; 1996 Jul; 55(1):68-74. PubMed ID: 8793060
    [Abstract] [Full Text] [Related]

  • 40. Gonadotropin-releasing hormone, estradiol, and inhibin regulation of follicle-stimulating hormone and luteinizing hormone surges: implications for follicle emergence and selection in heifers.
    Haughian JM, Ginther OJ, Diaz FJ, Wiltbank MC.
    Biol Reprod; 2013 Jun; 88(6):165. PubMed ID: 23658431
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.